Opinion: Once undruggable, the Wnt/β-catenin pathway shows increasing promise
Early-stage clinical data from our company and others point to the Wnt/β-catenin pathway as a new avenue for targeting multiple cancer types. For more than four decades, the “big four” oncology targets—KRAS, MYC, TP53, and Wnt/β-catenin —have represented a holy grail for cancer drug development. Each plays a critical role in tumor biology and is …
Opinion: Once undruggable, the Wnt/β-catenin pathway shows increasing promise Read More »
